Wockhardt Aims For $12m Annual Savings Through US Restructuring
Plus Serum Vaccines Operation And Diabetes Biosimilars Could Bring Firm Back To Profitability
Wockhardt expects to save up to $12m through restructuring its US business, eyeing up a potential return to profitability by 2025.
You may also be interested in...
Wockhardt’s US arm Morton Grove Pharmaceuticals, which is bound by a consent decree of permanent injunction, discontinues production to undertake an “orderly closure” and potential sale of its Illinois site. Indian parent firm taps contract manufacturers to service US market.
India’s Wockhardt has announced a fresh collaboration with the Serum Institute of India that will see the firm create a new sterile fill-and-finish facility in the UK, as part of plans to deliver an additional 150 million vaccine doses.
Lupin has announced a number of drug approvals in the US, as well as a biosimilar partnership in the Middle East and the launch of a novel fixed-dose triple combination drug in its native Indian market.